GlassScriptPhysician profile
Camille Roberts
NPI 1376519421
$4,995.36
in general payments reported to CMS, 2019-2025
25 companies · $1,813 in 2025
The $1,813 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $135 · 2021: $276 · 2022: $272 · 2023: $828 · 2024: $1,366 · 2025: $1,813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,204 · Consulting Fee: $1,400 · Education: $403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,203.87 |
| Consulting Fee | $1,400.00 |
| Education | $403.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $1,400.00 | 2025 | Sofdra |
| Abbvie INC. | $476.27 | 2019-2024 | Rinvoq, Skyrizi |
| Leo Pharma INC. | $328.84 | 2019-2025 | Anzupgo, Adbry |
| Janssen Biotech, INC. | $315.21 | 2020-2024 | Tremfya |
| Novartis Pharmaceuticals Corporation | $303.06 | 2021-2025 | |
| Pfizer INC. | $246.27 | 2023-2024 | |
| Arcutis Biotherapeutics, INC. | $237.64 | 2023-2024 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $223.03 | 2019-2024 | Dupixent, Libtayo |
| Incyte Corporation | $208.63 | 2022-2025 | Opzelura, Opzelura |
| E.R. Squibb & Sons, L.L.C. | $202.21 | 2023-2024 | Sotyktu |
| Amgen INC. | $197.45 | 2020-2024 | Otezla |
| Lilly USA, LLC | $165.63 | 2019-2024 | Olumiant, Taltz |
| Sun Pharmaceutical Industries INC. | $148.58 | 2019-2024 | Absorica Ld, Winlevi |
| Genzyme Corporation | $123.39 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $99.00 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $53.77 | 2022 | |
| Verrica Pharmaceuticals INC. | $47.84 | 2023-2024 | Ycanth |
| Tempus Ai, INC | $26.43 | 2024 | |
| Dusa Pharmaceuticals, INC. | $21.26 | 2019 | |
| Dermira, INC. | $17.99 | 2021 | |
| Dermavant Sciences, INC. | $17.58 | 2023 | Vtama |
| Mission Pharmacal Company | $12.78 | 2019 | |
| Prugen, INC. Pharmaceuticals | $11.72 | 2020 | |
| Novo Nordisk INC | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Camille Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.